Delivery Order SPE2DB24D2010-SPE2DB25FAAWW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10-count unit dose packaging) valued at $1,719.90 under a firm fixed-price delivery order contract type. The award was issued on August 27, 2025, with an ultimate completion date of August 28, 2025, with no set-aside designation applied. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the prime contractor on this delivery order, which represents...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets in unit-dose packaging of 10s, with a ceiling value of $5,072.71. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and deliver the pharmaceutical product to support...
- The Defense Logistics Agency awarded a delivery order valued at $2,126.74 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose tablets) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed price contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $999,999,999.00 and running through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $34,376.11 for UBRELVY 100 mg tablets (16-count unit dose packages) on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 through December 2026. The...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,381.64 for UBRELVY 50 MG tablets (10-unit dose packaging) on September 8, 2025, with completion scheduled for September 9, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $1,856.58 to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10 unit doses) on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract under the company's broader pharmaceutical supply agreement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAWWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-unit dose tablets) valued at $1,509.22 on August 19, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 million and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies an extensive portfolio of medications and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. UBRELVY is a migraine treatment medication, consistent with the company's demonstrated capability to deliver specialized pharmaceutical products across multiple therapeutic domains. The delivery will be performed at the contractor's Conshohocken, Pennsylvania location, reinforcing the company's role as a key logistics partner for federal medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/19/25 |